Drug intelligence / Profile preview

APC302

Development stage: Preclinical
Lead developer: AdjuTec Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

**APC302** is an investigational fixed-dose triple antibacterial combination developed by AdjuTec Pharma for multidrug-resistant Gram-negative bacterial infections. It combines **cefepime**, a cephalosporin beta-lactam antibiotic that inhibits bacterial penicillin-binding proteins, with **APC148**, a selective zinc-chelating inhibitor of metallo-beta-lactamases, and **avibactam**, an inhibitor of serine beta-lactamases. The combination is designed to restore cefepime activity against Enterobacterales producing metallo-beta-lactamases and serine beta-lactamases, including resistant pathogens carrying NDM, VIM, or IMP enzyme variants.

Other names: cefepime + APC148 + avibactam

Targets

Class A BL (Class A beta-lactamase)

Beyond the preview

Go deeper on APC302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APC302.

Explore the full profile